CytomX Therapeutics CTMX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's restricted cash?
- CytomX Therapeutics (CTMX) reported restricted cash of $1.53M in Q1 2026.
- How has CytomX Therapeutics's restricted cash changed year-over-year?
- CytomX Therapeutics's restricted cash increased by 48.5% year-over-year, from $1.03M to $1.53M.
- What is the long-term trend for CytomX Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), CytomX Therapeutics's restricted cash has grown at a 10.7% compound annual growth rate (CAGR), from $917K to $1.53M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.